Joint pain can make it difficult to stay active. Less activity can make weight management harder. Additional weight can then place even greater stress on painful joints. For many people living with osteoarthritis and obesity, this can become a difficult cycle.
Disclaimer: This article is for informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Please contact our medical providers at Coastal Primary Care to discuss your individual health needs and determine which treatment options may be appropriate for you.
Osteoarthritis (OA) is a chronic joint condition that causes pain, stiffness, swelling, and reduced mobility. While age, genetics, previous injuries, and repetitive stress can all contribute to osteoarthritis, excess body weight is one of the most important modifiable risk factors—particularly for osteoarthritis of the knees, hips, and ankles.
The encouraging news is that weight loss can be an important part of osteoarthritis management. For appropriate patients, medically supervised weight management—including the use of GLP-1 medications—may provide another tool for achieving meaningful, sustainable weight loss.
The relationship between obesity and osteoarthritis involves more than simply carrying additional pounds.
1. Extra Weight Means Extra Stress on Weight-Bearing Joints
Every day, the knees, hips, ankles, and lower back support the body's weight while we stand, walk, climb stairs, and perform everyday activities.
When body weight increases, the mechanical load placed on these joints also increases. Over time, this additional stress can contribute to damage of cartilage and other joint structures.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) identifies obesity as a leading risk factor for osteoarthritis of the knees, hips, and ankles.
This also helps explain why even a moderate amount of weight loss may matter. A person does not necessarily have to reach an "ideal" body weight before experiencing health benefits.
2. Obesity Can Promote Inflammation
Mechanical pressure is only part of the story.
Body fat is biologically active tissue. Excess body fat can be associated with increased levels of inflammatory substances circulating in the body. According to NIDDK, this inflammation may contribute to joint inflammation and increase the risk of osteoarthritis.
This means obesity can potentially affect joint health in two important ways:
- increasing the physical load placed on joints, and
- contributing to an inflammatory environment within the body.
For someone already experiencing osteoarthritis, these factors may make pain and mobility problems even more challenging
Osteoarthritis and obesity can reinforce one another.
A painful knee or hip may make walking, exercising, climbing stairs, or even completing routine daily activities difficult. As physical activity decreases, maintaining or losing weight can become harder.
Additional weight then places greater stress on the painful joint, potentially making activity even more difficult.
The cycle can look something like this:
Joint pain → less activity → weight gain or difficulty losing weight → greater joint stress → more difficulty moving
Breaking that cycle is an important goal of treatment.
For people who have overweight or obesity, losing weight can reduce stress on the knees, hips, and lower back and may also help decrease inflammation. NIDDK notes that people with osteoarthritis who lose weight may experience improvement in their symptoms.
Weight management can also provide benefits well beyond the joints. Obesity is associated with numerous chronic health conditions, including type 2 diabetes, high blood pressure, cardiovascular disease, sleep apnea, fatty liver disease, kidney disease, and other health problems.
Even modest weight loss can be meaningful. NIDDK notes that losing about 5% of starting body weight may be an appropriate initial goal for some people with overweight or obesity.
When joints hurt, avoiding exercise completely may seem logical. However, appropriate physical activity is an important part of osteoarthritis management.
NIDDK describes exercise as one of the best treatments for osteoarthritis because it can help decrease pain, improve flexibility, and improve mood.
The type and intensity of activity should be appropriate for the individual. For someone with significant knee or hip pain, a healthcare professional may recommend lower-impact activities rather than exercises that place excessive stress on the affected joint.
Weight management and physical activity can therefore work together: as weight decreases and movement becomes easier, some patients may find it more manageable to become active again.
Lifestyle changes—including nutrition, physical activity, sleep, and behavioral changes—remain fundamental components of weight management. But obesity is a chronic disease, and lifestyle changes alone may not produce or maintain sufficient weight loss for everyone.
For appropriate patients, prescription weight-management medications may be considered as part of a comprehensive medical treatment plan.
GLP-1 receptor agonists are one class of medications that can be used for weight management in appropriately selected patients. These medications mimic hormones involved in appetite and satiety, helping some patients feel fuller longer, reduce hunger, and consume fewer calories.
Importantly, GLP-1 medications are not osteoarthritis cures and should not be presented as replacements for appropriate arthritis treatment. Their relevance to osteoarthritis is primarily connected to weight management—and researchers are now studying this relationship more closely.
Importantly, GLP-1 medications are not osteoarthritis cures and should not be presented as replacements for appropriate arthritis treatment. Their relevance to osteoarthritis is primarily connected to weight management—and researchers are now studying this relationship more closely.
An important randomized clinical trial published in the New England Journal of Medicine in 2024 studied 407 adults with obesity and moderate knee osteoarthritis accompanied by at least moderate pain.
Participants received either once-weekly semaglutide 2.4 mg or placebo for 68 weeks, along with counseling on physical activity and a reduced-calorie diet.
The results were notable.
Participants receiving semaglutide lost an average of 13.7% of their body weight, compared with 3.2% in the placebo group.
They also experienced a significantly greater reduction in osteoarthritis-related knee pain. On the 100-point WOMAC pain scale, the average improvement was 41.7 points with semaglutide versus 27.5 points with placebo. Physical-function scores also improved more in the semaglutide group.
These findings do not mean that everyone with osteoarthritis should take a GLP-1 medication. They do, however, provide important evidence that substantial medically managed weight loss can have meaningful effects on both weight and symptoms in certain people living with obesity and knee osteoarthritis.
Weight management should not simply be about reaching a number on a scale. It should focus on improving overall health, mobility, and quality of life.
At Coastal Primary Care, our medically supervised weight-loss program takes an individualized approach. For patients who qualify, GLP-1 medications may be incorporated into a comprehensive weight-management plan under medical supervision.
Medical oversight is important because these medications are prescription treatments and are not appropriate for everyone. A healthcare professional should review a patient's health history, medications, weight-related conditions, potential contraindications, treatment goals, and possible side effects before determining whether GLP-1 therapy is appropriate.
For patients struggling with both obesity and osteoarthritis, successful weight management may mean more than seeing a lower number on the scale. It may mean less pressure on painful joints, improved mobility, greater ability to exercise, and better overall metabolic health.
If excess weight is contributing to knee, hip, ankle, or lower-back discomfort, addressing obesity can be an important part of protecting your long-term health.
Coastal Primary Care offers a medically supervised weight-loss program, including GLP-1 treatment for appropriate patients.
Talk with our medical team to determine whether a medically supervised weight-management program may be right for you.
GLP-1 medications require medical evaluation and are not appropriate for every patient. Individual weight-loss and health outcomes vary. Osteoarthritis symptoms should be evaluated by a qualified healthcare professional.
Sources
New England Journal of Medicine — GLP-1 Receptor Agonists and Osteoarthritis
National Institute of Diabetes and Digestive and Kidney Diseases — Health Risks of Overweight & Obesity
NIDDK — Treatment for Overweight & Obesity
New England Journal of Medicine — Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
